Literature DB >> 15047922

Recent advances in melanoma biology.

Cliff Perlis1, Meenhard Herlyn.   

Abstract

The incidence and mortality rates of melanoma have increased at annual rates of 2%-3% for the last 30 years. Disseminated disease is largely refractory to cytotoxic chemotherapy and is almost universally fatal. Several recent advances in melanoma biology offer new strategies for potentially treating this aggressive malignancy. This review focuses on three significant advances involving tumor initiation, etiology, and progression. New experimental models reveal a direct role for UV-B light in initiating melanomas in human skin. Studies on E- and N-cadherin elucidate the importance of local homeostatic mechanisms in regulating tumor progression. Finally, several discoveries concerning apoptotic mechanisms in melanoma suggest strategies for future treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047922     DOI: 10.1634/theoncologist.9-2-182

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  25 in total

1.  Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.

Authors:  Vladimir N Ivanov; Michael A Partridge; Sarah X L Huang; Tom K Hei
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

2.  Microphthalmia-associated transcription factor/T-box factor-2 axis acts through Cyclin D1 to regulate melanocyte proliferation.

Authors:  L Pan; X Ma; B Wen; Z Su; X Zheng; Y Liu; H Li; Y Chen; J Wang; F Lu; J Qu; L Hou
Journal:  Cell Prolif       Date:  2015-10-21       Impact factor: 6.831

3.  NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels.

Authors:  Satoshi Kashiwagi; Yotaro Izumi; Takeshi Gohongi; Zoe N Demou; Lei Xu; Paul L Huang; Donald G Buerk; Lance L Munn; Rakesh K Jain; Dai Fukumura
Journal:  J Clin Invest       Date:  2005-06-09       Impact factor: 14.808

4.  Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo.

Authors:  Jennifer M Roth; Abebe Akalu; Anat Zelmanovich; Desiree Policarpio; Bruce Ng; Shannon MacDonald; Silvia Formenti; Leonard Liebes; Peter C Brooks
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  Honokiol inhibits melanoma stem cells by targeting notch signaling.

Authors:  Gaurav Kaushik; Anand Venugopal; Prabhu Ramamoorthy; David Standing; Dharmalingam Subramaniam; Shahid Umar; Roy A Jensen; Shrikant Anant; Joshua M V Mammen
Journal:  Mol Carcinog       Date:  2014-12-09       Impact factor: 4.784

6.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

7.  Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.

Authors:  Geoffrey E Johnson; Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

8.  Loss of the eukaryotic initiation factor 3f in melanoma.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; Stanley P L Leong; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-10       Impact factor: 4.784

9.  Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.

Authors:  Vladimir N Ivanov; Hongning Zhou; Michael A Partridge; Tom K Hei
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Authors:  Hong Yu; Ronan McDaid; John Lee; Patricia Possik; Ling Li; Suresh M Kumar; David E Elder; Patricia Van Belle; Phyllis Gimotty; Matt Guerra; Rachel Hammond; Katharine L Nathanson; Maria Dalla Palma; Meenhard Herlyn; Xiaowei Xu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.